We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adicet Bio, Inc. (ACET - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Adicet Bio, Inc. is a member of our Medical group, which includes 914 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACET's full-year earnings has moved 21.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACET has returned about 3.8% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.1% on a year-to-date basis. This shows that Adicet Bio, Inc. is outperforming its peers so far this year.
Agilent Technologies (A - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 9.1%.
For Agilent Technologies, the consensus EPS estimate for the current year has increased 1.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual companies and currently sits at #150 in the Zacks Industry Rank. Stocks in this group have gained about 5.7% so far this year, so ACET is slightly underperforming its industry this group in terms of year-to-date returns.
Agilent Technologies, however, belongs to the Medical - Products industry. Currently, this 84-stock industry is ranked #102. The industry has moved -16.1% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adicet Bio, Inc. and Agilent Technologies as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adicet Bio, Inc. (ACET - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Adicet Bio, Inc. is a member of our Medical group, which includes 914 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACET's full-year earnings has moved 21.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACET has returned about 3.8% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.1% on a year-to-date basis. This shows that Adicet Bio, Inc. is outperforming its peers so far this year.
Agilent Technologies (A - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 9.1%.
For Agilent Technologies, the consensus EPS estimate for the current year has increased 1.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual companies and currently sits at #150 in the Zacks Industry Rank. Stocks in this group have gained about 5.7% so far this year, so ACET is slightly underperforming its industry this group in terms of year-to-date returns.
Agilent Technologies, however, belongs to the Medical - Products industry. Currently, this 84-stock industry is ranked #102. The industry has moved -16.1% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adicet Bio, Inc. and Agilent Technologies as they could maintain their solid performance.